Hims & Hers Q1 Miss Masks Guidance Raise, Subscriber Surge

Hims & Hers Health shares dropped roughly 11% in after-hours trading Monday after the company reported first-quarter results that missed on both the top and bottom lines. The GAAP loss of $0.40 per share compared with a loss of $0.03 a year ago, while revenue of $520.4 million, up 87% from $278.2 million, fell short of the Street's expectations.

The immediate sell-off reflects a simple read: a miss is a miss. A closer look at the numbers, however, shows the miss was driven by a temporary factor that management expects to reverse starting in the second quarter.

The Novo Deal Distortion

The company attributed the earnings shortfall to a temporary impact from its recently announced partnership with Novo Nordisk. The deal, which involves Hims & Hers offering compounded semaglutide through its platform, created a one-time cost or revenue recognition timing issue that depressed the quarter's results. Management stated on the call that this impact will become a tailwind in Q2 and beyond.

That explanation matters for traders trying to decide whether the after-hours drop is an overreaction. The adjusted EBITDA figure, which strips out some of the noise, rose 115% to $65.7 million from $30.6 million a year earlier. Subscriber growth accelerated to 74%, reaching 2.97 million. These metrics suggest the underlying business momentum remained intact despite the headline miss.

Guidance Raise and Subscriber Growth

Perhaps the most important signal in the release was the guidance raise. Hims & Hers lifted its full-year adjusted EBITDA forecast to $300 million to $320 million, up from the prior range of $270 million to $300 million. The revenue outlook was also raised, with the company now projecting $2.30 billion to $2.40 billion for the full year. The fact that management felt confident enough to raise guidance immediately after a quarter that missed consensus indicates the Novo deal impact is indeed transitory.

Subscriber growth of 74% is a hard number that cannot be dismissed. The company added nearly 1.3 million net new subscribers over the past year, expanding its base to almost 3 million. That kind of growth, combined with rising average revenue per subscriber, provides a cushion against one-time deal-related costs.

Margins and the Path to Profitability

The adjusted EBITDA margin expanded to 12.6% from 11.0% a year ago, reflecting operating leverage from the scaling subscriber base. The GAAP loss widened because of the Novo deal costs. The adjusted profitability metric, however, shows the core business is generating cash. With full-year adjusted EBITDA guidance now at $300 million to $320 million, the company is signaling a significant ramp in the back half of the year. If Hims & Hers hits the midpoint of that range, it would imply an adjusted EBITDA margin of roughly 13% to 14% on the guided revenue, up from the 12.6% in Q1.

Post-Print Stock Setup

The after-hours decline of about 11% puts the stock at levels that may attract buyers who focus on the guidance raise rather than the Q1 miss. The key question for Tuesday's regular session is whether the market will price in the temporary nature of the Novo impact or treat the miss as a reason to reset expectations lower. The raised EBITDA guidance implies a significant ramp in the back half of the year, and if the company delivers on that, the post-earnings dip could look like a buying opportunity.

The pattern of a temporary deal impact masking underlying growth is not unique. LY Corp recently reported a similar dynamic, where a one-time factor depressed results but guidance pointed to a rebound. For broader market context, see stock market analysis.

The next concrete catalyst will be the Q2 report, where management expects the Novo deal to begin contributing positively. Until then, the stock's reaction will depend on whether traders believe the temporary-impact narrative.